Anti-Herpes Virus Activity of 5-Methoxymethyl-2′-Deoxycytidine in Combination with Deaminase Inhibitors
- 1 August 1990
- journal article
- Published by SAGE Publications in Antiviral Chemistry and Chemotherapy
- Vol. 1 (4) , 255-262
- https://doi.org/10.1177/095632029000100405
Abstract
5-Methoxymethyl-2′-deoxycytidine (MMdCyd) is an anti-metabolite with selective anti-herpes activity and low cytotoxicity. MMdCyd is dependent upon initial activation by the viral-induced deoxythymidine-deoxycytidine (dThd/dCyd) kinase for its activity against herpes simplex virus (HSV). Antiviral activity of MMdCyd is cell-dependent and is influenced by the deaminase content of the cell line used for assays. The antiviral potency against HSV-1 in this study was higher in RK-13 cells (ED50 3–5 μm) than in Vero and HEP-2 cells (ED50 14–26 μm). The potency of MMdCyd increased approximately 20-fold against HSV-1 and twofold against HSV-2 in the presence of tetrahydrodeoxyuridine (H4dUrd; which inhibits both dCyd deaminase and dCMP deaminase) in Vero cells. MdCyd in combination with H4dUrd was effective in preventing the cytopathogenic effect of HSV-1 and decreasing the production of infectious virus particles. The IC99 (concentration required to reduce the yield of infectious virus obtained 72 h after infection by 99% relative to control cultures) was 1.6 μm. In combination with tetrahydrouridine (H4Urd; an inhibitor of Cyd/dCyd deaminase) the potency of MMdCyd was only slightly enhanced (ED50 7–8 μm). Dihydrodeoxyuridine and deoxyuridine reversed the antiviral activity of MMdCyd. The minimum cytotoxic concentration for rapidly dividing cells (RK-13, HEP-2 and Vero) for MMdCyd was greater than 3 mm. H4Urd and H4dUrd were devoid of cytotoxicity and antiviral activity up to 2.12 mm (the highest concentration tested). Diacetyl-MMdCyd (pro-drug form) was approximatewly 20 times less potent than MMdCyd.Keywords
This publication has 32 references indexed in Scilit:
- Antiherpes virus activity and effect on deoxyribonucleoside triphosphate pools of (E)-5-(2-bromovinyl)-2′-deoxycytidine in combination with deaminase inhibitorsAntiviral Research, 1990
- Activity of 5-bromovinyl-2′-deoxycytidine in combination with deaminase inhibitors against herpes simplex virus type 1 : Philip J. Aduma, Sagar V. Gupta and Erik De Clercq, Department of Physiological Sciences, WCVM, University of Saskatchewan, Saskatoon, Canada and Rega Institute for Medical Research, Katholieke University, Leuven, BelgiumAntiviral Research, 1988
- Phosphorolysis of (E)-5-(2-bromovinyl)-2'-deoxyuridine (BVDU) and other 5-substituted-2'-deoxyuridines by purified human thymidine phosphorylase and intact blood plateletsBiochemical Pharmacology, 1983
- Genital Herpes Simplex Virus Infections: Clinical Manifestations, Course, and ComplicationsAnnals of Internal Medicine, 1983
- Selective antiherpes agentsTrends in Pharmacological Sciences, 1982
- On the mechanism of selective inhibition of herpesvirus replication by (E)-5-(2-bromovinyl)-2'-deoxyuridine.Proceedings of the National Academy of Sciences, 1981
- Combination chemotherapy: interaction of 5-methoxymethyldeoxyuridine with adenine arabinoside, 5-ethyldeoxyuridine, 5-iododeoxyuridine, and phosphonoacetic acid against herpes simplex virus types 1 and 2Antimicrobial Agents and Chemotherapy, 1980
- (E)-5-(2-Bromovinyl)-2'-deoxyuridine: a potent and selective anti-herpes agent.Proceedings of the National Academy of Sciences, 1979
- Comparison of the Antiviral Effects of 5-Methoxymethyl-deoxyuridine with 5-Iododeoxyuridine, Cytosine Arabinoside, and Adenine ArabinosideAntimicrobial Agents and Chemotherapy, 1975
- Cytidine Deaminase from Escherichia coliJournal of Biological Chemistry, 1971